ResultsIQ

ResultsIQ › Latest results › Cohance Lifesciences Limited

Cohance Lifesciences Limited Q4 FY26 earnings call summary

NSE: COHANCE · BSE: 543064

Earnings call of 12 May 2026, summarised by AI from the filing.

Cohance FY26 revenue ₹22.68 billion, down 13%; Q1 FY27 to be low, growth to return from H2 FY27.

Key takeaways

  1. FY26 results Revenue ₹22.68 billion, down approximately 13% year-on-year; adjusted EBITDA ₹4.77 billion; EBITDA margin 21%.
  2. Guidance Q1 FY27 to be low on revenue and EBITDA; growth to return from H2 FY27; FY27 capex nearly ₹3 billion.
  3. Change Umang Vohra joined as Executive Chairman and Group CEO, marking a leadership transition.
  4. Driver Phase 3 pipeline at 10 programs and two new commercial molecules expected to contribute in FY27.
  5. Risk Destocking in two large commercial molecules impacted FY26 by around ₹260 crore; return expected in FY27 but value not confirmed.

Original filing on BSE

Cohance Lifesciences Limited Q1 FY27 results

As filed: Revenue ₹422 cr (−23% year on year), EBITDA ₹1.2 cr (−99% year on year), PAT −₹45.2 cr (−198% year on year), EBITDA margin 0.3% (−1,000 bps).

The Q1 FY27 score, against the company's own trend, is for premium members.

Earlier results and the share price after them

  • Q4 FY26: Revenue ₹619 cr (+54% year on year), EBITDA ₹98.7 cr (+33% year on year), PAT ₹8.3 cr (−30% year on year), EBITDA margin 15.9% (−247 bps). Score 55 of 100, In line with trend. EBITDA margin fell 247 bps year on year. Tax rate 58%. Not enough history for a trend yet: scored on growth alone. Profit fell 20% from last quarter. Share price after the results: −12.6% in 30 days (Nifty 500: −0.8%).
  • Q3 FY26: Revenue ₹482 cr, EBITDA ₹103 cr, PAT ₹47.3 cr, EBITDA margin 21.3%. Not scored. No result for the same quarter last year. Share price after the results: −15.6% in 29 days (Nifty 500: −9.6%).
  • H1 FY26: Revenue ₹981 cr, EBITDA ₹236 cr, PAT ₹147 cr, EBITDA margin 24.1%. Not scored. No result for the same half-year last year. Share price after the results: −22.3% in 30 days (Nifty 500: −0.5%).
  • Q1 FY26: Revenue ₹484 cr, EBITDA ₹104 cr, PAT ₹53.0 cr, EBITDA margin 21.5%. Not scored. No result for the same quarter last year. Share price after the results: −0.6% in 30 days (Nifty 500: +2.2%).
  • Q4 FY25: Revenue ₹330 cr, EBITDA ₹66.0 cr, PAT ₹44.0 cr, EBITDA margin 20.0%. Not scored. No result for the same quarter last year. Share price after the results: −14.9% in 30 days (Nifty 500: +3.7%).

Past price moves after results do not indicate future moves. Not a recommendation.

Cohance Lifesciences Limited earnings call, investor presentation and press release summaries

Figures from the company's filings with NSE and BSE. Not investment advice.